MWM
MIST icon

Mascoma Wealth Management’s Milestone Pharmaceuticals MIST Stock Holding History

Mascoma Wealth Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$363 – 548
2023
Q1 		$363 Hold
100
– – ﹤0.01% 582
2022
Q4 		$396 Buy
+100
New +$526 ﹤0.01% 607

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Mascoma Wealth Management's MIST Position: Q2 2023 in Review

Mascoma Wealth Management sold out of Milestone Pharmaceuticals (MIST) in Q2 2023, closing a stake of 100 shares — an estimated $363 sold.

Mascoma Wealth Management first reported a position in MIST in Q4 2022 and held it in 2 quarters. The position peaked at $396 in Q4 2022. 48 funds tracked by Wall St. Rank hold MIST as of Q2 2023.

  • Mascoma Wealth Management reported no remaining Milestone Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Mascoma Wealth Management sold 100 Milestone Pharmaceuticals shares in Q2 2023, an estimated $363.
  • Mascoma Wealth Management first reported a position in Milestone Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Mascoma Wealth Management's Milestone Pharmaceuticals position peaked at $396 in Q4 2022.
  • 48 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2023.

Based on Mascoma Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.